Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia

Withdrawn before enrolling · Phase 2

Conditions studied: Anemia

In brief

The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.

Key facts

Study ID

NCT00481624

Run by

University of Louisville

People needed

0

Starts

2007-05-01

Expected to finish

2009-11-01

Last updated by the study team

2018-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed small cell or non small cell lung cancer
• Stage III or Stage IV lung cancer
• Platinum containing chemotherapy induced anemia (< 10 g/dl Hb)
• Cancer related anemia (<10 g/dl Hb) at time of initiation of chemotherapy
• ECOG performance status of 0,1, or 2
• Informed consent
• Age>18
• Expected to receive platinum based outpatient chemotherapy for at least nine weeks

You may not qualify if…

• Pregnant women
• Intolerance to epoetin alfa or parenteral iron
• More than 2 cycles of the planned platinum chemotherapy at time of enrollment
• Chronic GI bleed (> than 4 weeks positive hemoccult or gastroccult)
• Ferritin > 500 mg/dl
• Anemia due to other causes than cancer or chemotherapy
• Previous parenteral iron therapy
• Uncontrolled hypertension (systolic BP > 160, diastolic > 100 mmHg)

Where it is running

• James Graham Brown Cancer Center — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.